Daiichi Sankyo
Chad Bower is an accomplished executive with extensive experience in oncology market access and strategic leadership. Currently serving as Executive Director of Oncology Market Access at Daiichi Sankyo, Inc., since January 2019, Chad has built and led teams focused on market shaping strategies. Previously, Chad held various leadership roles at Johnson & Johnson and The Janssen Pharmaceutical Companies, where responsibilities included developing market access strategies for oncology products like Darzalex and ZYTIGA. Early career experience includes positions at Ethicon, Pfizer, and Wells Fargo, where Chad demonstrated strong leadership and sales performance. Chad holds an MBA from the University of Texas and a BS in Biological Sciences from Eastern New Mexico University, complemented by management training at Rutgers and UCLA Anderson.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.